More than 500 molecules have been identified as components of Cannabis sativa (C. sativa), of which the most studied is Δ⁹-tetrahydrocannabinol (Δ⁹-THC). Several studies have suggested that Δ⁹-THC exerts diverse biological effects, ranging from fragmentation of DNA to behavioral disruptions. Currently, it is accepted that most of the pharmacological properties of Δ⁹-THC engage the activation of the cannabinoid receptors, named CB₁ and CB₂. Interestingly, multiple pieces of evidence have suggested that the cannabinoid receptors play an active role in the modulation of several diseases leading to the design of synthetic cannabinoid-like compounds. Advances in the development of synthetic CB₁ cannabinoid receptor selective agonists as therapeutical approaches are, however, limited. This review focuses on available evidence searched in PubMed regarding the synthetic CB₁ cannabinoid receptor selective agonists such as AM-1235, arachidonyl-2′ chloroethylamide (ACEA), CP 50,556–1 (Levonantradol), CP-55,940, HU-210, JWH-007, JWH-018, JWH-200 (WIN 55,225), methanandamide, nabilone, O-1812, UR-144, WIN 55,212-2, nabiximols, and dronabinol. Indeed, it would be ambitious to describe all available evidence related to the synthetic CB₁ cannabinoid receptor selective agonists. However, and despite the positive evidence on the positive results of using these compounds in experimental models of health disturbances and preclinical trials, we discuss evidence in regards some concerns due to side effects.

超过 500 个分子已被鉴定为大麻 (C. sativa)的成分，其中研究最多的是 Δ ⁹ -四氢大麻酚 (Δ ⁹ -THC)。几项研究表明，Δ ⁹ -THC 发挥多种生物学效应，从 DNA 片段化到行为破坏。^{目前，公认 Δ 9} -THC 的大部分药理特性与大麻素受体的激活有关，称为 CB ₁和 CB ₂. 有趣的是，多项证据表明，大麻素受体在调节多种疾病中发挥着积极作用，从而导致了合成大麻素样化合物的设计。然而，作为治疗方法的合成 CB ₁大麻素受体选择性激动剂的开发进展有限。本综述重点关注在 PubMed 中搜索到的关于合成 CB _{1的可用证据}大麻素受体选择性激动剂，例如 AM-1235、花生四烯酰-2' 氯乙酰胺 (ACEA)、CP 50,556–1 (Levonantradol)、CP-55,940、HU-210、JWH-007、JWH-018、JWH-200 (WIN 55,225) , methanandamide, nabilone, O-1812, UR-144, WIN 55,212-2, nabiximols, 屈大麻酚。_{事实上，描述与合成 CB 1}大麻素受体选择性激动剂相关的所有可用证据将是雄心勃勃的。然而，尽管在健康干扰的实验模型和临床前试验中使用这些化合物的积极结果有积极的证据，但我们讨论了关于副作用引起的一些担忧的证据。